Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 studyJoyce F. Liu, Ursula A. Matulonis, Michael J. Birrer et al.|The Lancet Oncology|2014Cited by 586